Stockscreener 앱 받기
0.244
1.46%
0.0035
시간 외 거래:
.24
-0.004
-1.64%
전일 마감가:
$0.2405
열려 있는:
$0.258
하루 거래량:
2.24M
Relative Volume:
2.20
시가총액:
$22.42M
수익:
순이익/손실:
$-40.23M
주가수익비율:
-0.5708
EPS:
-0.4275
순현금흐름:
$-34.82M
1주 성능:
-19.79%
1개월 성능:
-35.62%
6개월 성능:
-89.34%
1년 성능:
-80.63%
1일 변동 폭
$0.2221
$0.27
1주일 범위
$0.2221
$0.3082
52주 변동 폭
$0.2221
$3.62
Context Therapeutics Inc Stock (CNTX) Company Profile
명칭
Context Therapeutics Inc
전화
267-225-7416
주소
2001 MARKET STREET, PHILADELPHIA
Compare CNTX vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
0.244 | 22.42M | 0 | -40.23M | -34.82M | -0.4275 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-18 | 개시 | Guggenheim | Buy |
| 2025-04-21 | 개시 | William Blair | Outperform |
| 2025-01-08 | 개시 | JMP Securities | Mkt Outperform |
| 2024-11-25 | 개시 | D. Boral Capital | Buy |
| 2024-05-16 | 개시 | Piper Sandler | Overweight |
Context Therapeutics Inc 주식(CNTX)의 최신 뉴스
New Strong Sell Stocks for October 15th - Zacks Investment Research
Valion Bio, Inc. (VBIO) Stock Price & News - Syfe
New Strong Sell Stocks for October 13th - Zacks Investment Research
Context Therapeutics (CNTX) Edges Higher as Penny Stock Holds Above $0.30Dynamic Hedging - https://www.dars.gov.et/
Scienture Holdings, Inc. (SCNX) Stock Price & News - Syfe
Kairos Pharma, Ltd. (KAPA) Stock Price & News - Syfe
Knight Therapeutics: Business Profile and TSX Market Context - Kalkine Media
Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000 - The Motley Fool
Context Therapeutics Begins Phase I Trial of Bispecific Antibody in Nectin-4-Positive Tumors - GenomeWeb
Context Therapeutics Doses First Patient in Phase 1 Trial of CT-202 - marketscreener.com
Context Therapeutics Doses First Patient in Phase 1 Trial of CT-202 for Solid Tumors - quiverquant.com
A cancer treatment enters human testing for three cancers - Stock Titan
Longeveron Inc. Class A (LGVN) Stock Price & News - Syfe
CalciMedica, Inc. (CALC) Stock Price & News - Syfe
Can Context Therapeutics (NASDAQ:CNTX) Afford To Invest In Growth? - simplywall.st
Context Therapeutics (CNTX) Edges Up 1.56% as Stock Holds Above $0.37 SupportRisk Reward Setups - vinanet.vn
Lantern Pharma Inc. (LTRN) Stock Price & News - Syfe
Actuate Therapeutics, Inc. (ACTU) Stock Price & News - Syfe
Onconetix, Inc. (ONCO) Stock Price & News - syfe.com
Bullfrog AI Holdings, Inc. (BFRG) Stock Price & News - Syfe
Valion Bio, Inc. (VBIO) Stock Price & News - Syfe
Context (CNTX) Q2 2026 Results: The Bottom-Line Figure Trails Its Comparison under the Current Snapshot; Stock Move: The Market Price Declines 3.77% in the Latest SessionEstimate Revision Count - vinanet.vn
Context Therapeutics Inc. Revenue Breakdown – NASDAQ:CNTX - TradingView
Context (CNTX) Q2 2026 Results: The Available Earnings Metric Delivers a Miss for This Review; Post-Report: Shares Finish 2.19% Up on the DayNext Quarter Guidance - vinanet.vn
Context (CNTX) Quarterly Figures: EPS Comes in Below Forecast for This Review; Post-Earnings: Shares Fall 1.81% - vinanet.vn
Enterprise value to EBITDA forward of Context Therapeutics Inc. – NASDAQ:CNTX - TradingView
a2026mar-contextxcorpdec.htm - SEC.gov
MPM BioImpact reports 1.4% stake in Context Therapeutics (CNTX) common stock - Stock Titan
Blue Owl Capital Holdings (CNTX) reports 3.19% beneficial stake in Context Therapeutics - Stock Titan
Maxim Group Maintains Context Therapeutics(CNTX.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Context Therapeutics (CNTX) Slips 6.6% to $0.45, Pressing Key Support at $0.43Factor Rotation - dars.gov.et
Context Therapeutics Narrows Pipeline as Quarterly Loss Widens - MyChesCo
Enterprise value to EBITDA forward of Context Therapeutics, Inc. – FWB:6K9 - TradingView
Context Therapeutics (CNTX) Slips 6.6% to $0.45, Pressing Key Support at $0.43Hagopian Line - vinanet.vn
LifeSci Capital Maintains Context Therapeutics(CNTX.US) With Hold Rating, Announces Target Price $2 - Moomoo
LifeSci Capital downgrades Context Therapeutics (CNTX) to a Hold - The Globe and Mail
Context Therapeutics Inc (CNTX) Stock News Today - TradingKey
Context Therapeutics Inc (CNTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Context drops bispecific T-cell engager on cost-cutting initiative - Yahoo Finance
Context Therapeutics Inc. Stock 12‑Month Price Target Cut to $4.56, Implies 557% Upside - TradingView
Context Therapeutics advancing CT-202 into clinic in Australia - bioworld.com
Context Therapeutics Stock (CNTX) is Falling After Hours: Here's What's Driving the Move - TradingView
Context Therapeutics (NASDAQ:CNTX) Announces Earnings Results, Misses Expectations By $0.05 EPS - marketbeat.com
Context Therapeutics Highlights Progress in T Cell Engager Pipeline - TipRanks
Context Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Context Therapeutics Q2 net loss widens on higher R&D costs - TradingView
Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress - The Manila Times
Context Therapeutics Ends CT-95, Focuses on Two Cancer Programs - Stock Titan
Context Therapeutics Inc. 1H 2026: Net income $(23.24)M, Diluted EPS $(0.24) — 10-Q Summary - TradingView
Context Therapeutics (NASDAQ: CNTX) reports $23.2 million loss and cash runway - Stock Titan
Context Therapeutics Inc (CNTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.22%
자본화:
|
볼륨(24시간):